Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis Clinical Trial

Official title:

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03954327
• Other study ID #: Pro00082571
• Status: Completed
• Phase: Phase 2
• Start date: March 1, 2021
• Est. completion date: January 1, 2024

Study information

• Verified date: February 2024
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

Description:

Primary endpoint: Change in mean percentage of alkaline phosphatase (ALP) reduction in cART vs. placebo at 6 and 12 months. Secondary endpoints: 1. Serum biochemistries bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) will be studied as continuous variables. 2. Composite endpoint used for the POISE study [A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis]: (i) reduction of ALP to < 1.67 upper limit of normal, (ii) normalization of bilirubin within upper limit of normal (ULN) and (iii) reduction of ALP by > 15% at 6 and 12 months. 3. Symptomatic evaluation performed using the PBC-40 to assess five symptom domains relating to fatigue, itch, cognitive symptoms, social and emotional symptoms, and other symptoms. 4. Histological change in grade and stage of PBC using the Nakanuma scoring system for a subgroup of patients undergoing liver biopsy [liver biopsy not compulsory for study]. 5. Serial human betaretrovirus measurement in peripheral blood and cellular immune response to viral peptides.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: January 1, 2024
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• over 18 years old of either sex,
• Anti-mitochondrial antibody +ve or liver histology compatible with PBC,
• stable UDCA dose of 13-15 mg/kg for > 12 months or intolerant to UDCA,
• ALP at least 1.67 x ULN or abnormal bilirubin less than 2x ULN
• able to read and sign informed consent form.

Exclusion Criteria:

• subjects with baseline total bilirubin > 2 x ULN,(patients meeting inclusion criteria stabilized on second line therapies including obeticholic acid or bezafibrate over 12 months or more may be enrolled).
• use of non-standard or experimental therapy within the last 6 months,
• advanced liver disease: INR > 1.2 ULN, Albumin < 35 g/L lower limit of normal, platelets < 120,000/microL unless varices with risk of bleeding excluded by endoscopy within the last 6 months, Childs Pugh class B or C cirrhosis, presence of grade 2 varices or previous variceal hemorrhage, encephalopathy, ascites or need for liver transplantation within the next two years;
• secondary diagnosis such as HIV, viral hepatitis, drug induced liver injury, extrahepatic biliary obstruction, primary sclerosing cholangitis, metabolic liver - regular use of > 30g alcohol/day in the last year;
• a predicted survival of less than 3 years from malignant or other life threatening disease;
• hepatic mass consistent with hepatocellular carcinoma ;
• previous allergic reaction to study medications;
• Glomerular Filtration Rate less than < 30 mL/min as measured Cockcroft-Gault formula;
• pregnancy, breast-feeding or pre-menopausal patients not using contraception.

Related Conditions & MeSH terms

• Cholangitis
• Liver Cirrhosis, Biliary
• Primary Biliary Cholangitis

Intervention

Drug:
• Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
• Raltegravir
Raltegravir (RTF) 600 mg two tablets by mouth once per day
• Placebo Oral Capsule [CEBOCAP]
Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta
Canada	University of Montreal	Montréal	Quebec
Canada	Royal University Hospital	Saskatoon	Saskatchewan
Canada	University of Toronto	Toronto	Ontario
Canada	St Paul's Hospital, University of British Columbia	Vancouver	British Columbia
Canada	Vancouver General Hospital, University of Brittish Columbia	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
University of Alberta	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in alkaline phosphatase levels	Mean changes in alkaline phosphatase levels after 12 months treatment with combination antiretroviral therapy or placebo.	12 months
Secondary	Serial changes in alkaline phosphatase	Serial changes in alkaline phosphatase levels with combination antiretroviral therapy or placebo.	Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]
Secondary	Serial changes in ALT	Serial changes in ALT levels with combination antiretroviral therapy or placebo.	Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]
Secondary	Serial changes in bilirubin	Serial changes in bilirubin levels with combination antiretroviral therapy or placebo.	Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]
Secondary	Achievement of the composite biochemistry endpoint	(i) reduction of ALP to < 1.67 upper limit of normal, (ii) normalization of bilirubin within ULN and (iii) reduction of ALP by > 15%	6 and 12 months
Secondary	Human Betaretrovirus load in peripheral blood	Quantification of Human Betaretrovirus DNA or RNA levels in peripheral blood measured by Quantigene or polymerase chain reaction with therapy or placebo.	Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy
Secondary	Interferon gamma release to Human Betaretrovirus peptide stimulation	Concentration of interferon gamma released from peripheral blood mononuclear cells stimulated by Human Betaretrovirus peptides in vitro in response to treatment or placebo.	Evaluation at baseline, 6 months and end of RCT; then 6 monthly to end of open label therapy
Secondary	Liver histology	Liver histology will be measured in a scale for staging and grading disease using the Nakanuma scoring system. Scores for fibrosis, bile duct loss, and chronic cholestasis will be combined for staging: stage 1, total score of 0; stage 2, score 1-3; stage 3, score 4-6; and stage 4, score 7-9. Cholangitis activity and hepatitis activity will be graded as 0-3, respectively.	Pretreatment biopsy and 24 month biopsy after initiation of study therapy